English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#mibc search results

SScagliarini_'s profile picture. Medical Oncologist at AORN Cardarelli in Naples #GU cancers #RCC #kidneycancer #prostatecancer #bladdercancer #UC #Immunotherapy
Sarah Scagliarini, MD
 @SScagliarini_
Nov 21

#GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼

SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
0
2
10
0
627
ozdogan_md's profile picture. Oncologist. Cancer treatment & care in Turkey. Current advances, future directions and second opinion... Let's create a society which is not afraid of cancer!
Mustafa Özdoğan, MD
@ozdogan_md
Nov 21

FDA has approved perioperative pembrolizumab + enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) based on KEYNOTE-905 / EV-303. #BladderCancer #MIBC #Oncology #FDA #Pembrolizumab #EnfortumabVedotin #Immunotherapy #ADC #KEYNOTE905 #EV303…

ozdogan_md's tweet image. FDA has approved perioperative pembrolizumab + enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) based on KEYNOTE-905 / EV-303. #BladderCancer #MIBC #Oncology #FDA #Pembrolizumab #EnfortumabVedotin #Immunotherapy #ADC #KEYNOTE905 #EV303…
1
10
21
1
997
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Nov 10

#MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS

urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
0
7
16
4
1K
SWOG's profile picture. SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956.
SWOG Cancer Research Network
 @SWOG
14 h

S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0 or cT1) allow for bladder preservation? Systematic biopsies needed at post-NAT TURBT pre-registration. Co-PI: @siadaneshmand @uscnorris swog.org/clinical-trial…

SWOG's tweet image. S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0 or cT1) allow for bladder preservation? Systematic biopsies needed at post-NAT TURBT pre-registration. Co-PI: @siadaneshmand @uscnorris swog.org/clinical-trial…
0
3
4
0
330
AndreaNecchi's profile picture. Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Andrea Necchi
@AndreaNecchi
Aug 27

📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4…

AndreaNecchi's tweet image. 📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4…
AndreaNecchi's tweet image. 📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4…
3
54
141
29
19K
DrIacovelli's profile picture. Associate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy. Focused on GU cancers. Husband & father of 2 kids.
Roberto Iacovelli
@DrIacovelli
Oct 18

New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos

DrIacovelli's tweet image. New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos
DrIacovelli's tweet image. New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos
DrIacovelli's tweet image. New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos
DrIacovelli's tweet image. New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos
2
25
57
12
4K
brookmans76's profile picture. Professor of Urology @LMU_Muenchen, SVP Therapeutic Area Head Urologic Oncology @AuraBiosciences - former VP R&D J&J - Sports Medicine 🚵‍♀️Passionate Cyclist
Sabine D. Brookman-May
 @brookmans76
Oct 21

Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday

brookmans76's tweet image. Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday
brookmans76's tweet image. Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday
brookmans76's tweet image. Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday
brookmans76's tweet image. Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday
2
6
26
3
2K
DrFelixGuerrero's profile picture. MD PhD UroOncology @urologia12 @ROC_Urologia @HMHOSPITALES Scient Committee @GuardConsortium “Try not to become a man of success, rather become a man of value”
Félix Guerrero-Ramos
@DrFelixGuerrero
Jan 18, 2024

Dr. Solsona back on the stage with a great talk on #bladderpreservation for #MIBC at the IVO Masterclass Coordinators: @mjuanfi81 @DominguezEscrig @GuardConsortium

DrFelixGuerrero's tweet image. Dr. Solsona back on the stage with a great talk on #bladderpreservation for #MIBC at the IVO Masterclass Coordinators: @mjuanfi81 @DominguezEscrig @GuardConsortium
0
8
19
0
2K
AndreaNecchi's profile picture. Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Andrea Necchi
@AndreaNecchi
Sep 20, 2024

New data on neoadj IO in #MIBC from #IBCN24 OPTIMUS trial was a multicenter international study including neoadj Retifanlimab arm before RC in cis-ineligible or refusing pts | CD8+ tumor infiltration was the primary endpoint | pT0N0 rate was 40% in line with other neoadj IO…

AndreaNecchi's tweet image. New data on neoadj IO in #MIBC from #IBCN24 OPTIMUS trial was a multicenter international study including neoadj Retifanlimab arm before RC in cis-ineligible or refusing pts | CD8+ tumor infiltration was the primary endpoint | pT0N0 rate was 40% in line with other neoadj IO…
0
15
26
4
2K
GiuliaMarvaso84's profile picture. Radiation Oncologist at the European Institute of Oncology Milan; Assistant Professor at the University of Milan Oncology Department Italia 🇮🇹
Giulia Marvaso
 @GiuliaMarvaso84
May 5

Big news from #ESTRO25! Nivolumab + CRT shows striking improvement in MIBC outcomes for patients not undergoing RC! BCFFS: 70.3% vs 43.4% OS at 2y: 86.8% vs 60.5% (p=0.005) Well tolerated + good onc outcomes = a game-changer? Time for Phase III trial! #TMT #MIBC #immunotherapy

GiuliaMarvaso84's tweet image. Big news from #ESTRO25! Nivolumab + CRT shows striking improvement in MIBC outcomes for patients not undergoing RC! BCFFS: 70.3% vs 43.4% OS at 2y: 86.8% vs 60.5% (p=0.005) Well tolerated + good onc outcomes = a game-changer? Time for Phase III trial! #TMT #MIBC #immunotherapy
GiuliaMarvaso84's tweet image. Big news from #ESTRO25! Nivolumab + CRT shows striking improvement in MIBC outcomes for patients not undergoing RC! BCFFS: 70.3% vs 43.4% OS at 2y: 86.8% vs 60.5% (p=0.005) Well tolerated + good onc outcomes = a game-changer? Time for Phase III trial! #TMT #MIBC #immunotherapy
GiuliaMarvaso84's tweet image. Big news from #ESTRO25! Nivolumab + CRT shows striking improvement in MIBC outcomes for patients not undergoing RC! BCFFS: 70.3% vs 43.4% OS at 2y: 86.8% vs 60.5% (p=0.005) Well tolerated + good onc outcomes = a game-changer? Time for Phase III trial! #TMT #MIBC #immunotherapy
GiuliaMarvaso84's tweet image. Big news from #ESTRO25! Nivolumab + CRT shows striking improvement in MIBC outcomes for patients not undergoing RC! BCFFS: 70.3% vs 43.4% OS at 2y: 86.8% vs 60.5% (p=0.005) Well tolerated + good onc outcomes = a game-changer? Time for Phase III trial! #TMT #MIBC #immunotherapy
3
26
64
18
4K
Uroweb's profile picture. We are: 18,000+ urologists. We do: Numerous scientific meetings, CME accreditation, scientific publications, research, awareness and more.
European Association of Urology (EAU)
 @Uroweb
Jan 9

New Cheat Sheet on #MIBC! It covers adjuvant chemotherapy and immunotherapy roles, recent advancements in metastatic UC treatment, and combination therapy standards like EV + Pembrolizumab. #BladderCancer #EAUguidelines Download here: uroweb.org/guidelines/mus…

Uroweb's tweet image. New Cheat Sheet on #MIBC! It covers adjuvant chemotherapy and immunotherapy roles, recent advancements in metastatic UC treatment, and combination therapy standards like EV + Pembrolizumab. #BladderCancer #EAUguidelines Download here: uroweb.org/guidelines/mus…
1
47
133
77
21K
nataliagandur's profile picture. Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte Views Mine
Dra. María Natalia Gandur Quiroga
@nataliagandur
Aug 10, 2023

💫🌟Revolutionizing #MIBC Treatment: VI-RADS Scores Predict Success of #Immunotherapy 🚀🩺🌟💫 #MIBCResearch #InnovativeMedicine🌟💫 📢 **Exciting Findings**: PURE-01 trial reveals groundbreaking insights! 🌟 VI-RADS Power: Predicting post-neoadjuvant immunotherapy response in…

nataliagandur's tweet image. 💫🌟Revolutionizing #MIBC Treatment: VI-RADS Scores Predict Success of #Immunotherapy 🚀🩺🌟💫 #MIBCResearch #InnovativeMedicine🌟💫 📢 **Exciting Findings**: PURE-01 trial reveals groundbreaking insights! 🌟 VI-RADS Power: Predicting post-neoadjuvant immunotherapy response in…
0
12
20
3
3K
siadaneshmand's profile picture. Professor of Urology and Oncology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic Oncology Fellowship Director USC
Sia Daneshmand, M.D.
@siadaneshmand
Sep 21, 2024

⁦⁦@saumyg⁩ presenting trial concept - do all pts with #MIBC need neoadjuvant chemotherapy? LUMBER-NAC #ibcn ⁦@Decipher_VCYT⁩ ⁦@BladderCancerUS⁩

siadaneshmand's tweet image. ⁦⁦@saumyg⁩ presenting trial concept - do all pts with #MIBC need neoadjuvant chemotherapy? LUMBER-NAC #ibcn ⁦@Decipher_VCYT⁩ ⁦@BladderCancerUS⁩
3
5
39
0
2K
AndreaNecchi's profile picture. Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Andrea Necchi
@AndreaNecchi
Jul 29, 2024

Happy to provide the first announcement of a global consensus meeting that will be held in person and virtually on Saturday December 14 2024 at @SanRaffaeleMI the day after our #GURetreat24 | the topic will be the definition of clinical CR after neoadjuvant therapies for #MIBC

AndreaNecchi's tweet image. Happy to provide the first announcement of a global consensus meeting that will be held in person and virtually on Saturday December 14 2024 at @SanRaffaeleMI the day after our #GURetreat24 | the topic will be the definition of clinical CR after neoadjuvant therapies for #MIBC
2
12
37
2
2K
DrFelixGuerrero's profile picture. MD PhD UroOncology @urologia12 @ROC_Urologia @HMHOSPITALES Scient Committee @GuardConsortium “Try not to become a man of success, rather become a man of value”
Félix Guerrero-Ramos
@DrFelixGuerrero
Oct 11

‼️Primary vs progressive #MIBC 🤼Controversial topic 📉We publish on this in the October issue of @actasurologicas @RodriguezFaba 🏥@Urologia12 @cgdelcanizo @MarioHArroyo @H12Octubre 🔗Read it here: t.ly/cdaAk

DrFelixGuerrero's tweet image. ‼️Primary vs progressive #MIBC 🤼Controversial topic 📉We publish on this in the October issue of @actasurologicas @RodriguezFaba 🏥@Urologia12 @cgdelcanizo @MarioHArroyo @H12Octubre 🔗Read it here: t.ly/cdaAk
DrFelixGuerrero's tweet image. ‼️Primary vs progressive #MIBC 🤼Controversial topic 📉We publish on this in the October issue of @actasurologicas @RodriguezFaba 🏥@Urologia12 @cgdelcanizo @MarioHArroyo @H12Octubre 🔗Read it here: t.ly/cdaAk
DrFelixGuerrero's tweet image. ‼️Primary vs progressive #MIBC 🤼Controversial topic 📉We publish on this in the October issue of @actasurologicas @RodriguezFaba 🏥@Urologia12 @cgdelcanizo @MarioHArroyo @H12Octubre 🔗Read it here: t.ly/cdaAk
0
15
33
6
2K
DrMirallas's profile picture. Clinical Fellow @MDAndersonNews |Medical Oncol Drug Develop🫁 23-25 @VHIO | Onc Fellow 18-23 @vallhebron | Vocal 21-25 @COMBarcelona | Profesor 18-25 @SalutUIC
Oriol Mirallas MD
 @DrMirallas
Oct 18

#ESMO25 Presidential Session 💥 🙌🏽 Practice Changing Trials 👉🏽 KEYNOTE-905: Enfortumab Vedotin+Pembro Cisplatin inelegible va Pembro #MIBC 🗣️ Dr. Vulsteke ✅ EFS NR vs 15.7m HR 0.40 ✅ OS NR vs 41.7m HR 0.50 ✅ pCR 57.1 vs 8.6% @OncoAlert @myESMO @_SEOM

DrMirallas's tweet image. #ESMO25 Presidential Session 💥 🙌🏽 Practice Changing Trials 👉🏽 KEYNOTE-905: Enfortumab Vedotin+Pembro Cisplatin inelegible va Pembro #MIBC 🗣️ Dr. Vulsteke ✅ EFS NR vs 15.7m HR 0.40 ✅ OS NR vs 41.7m HR 0.50 ✅ pCR 57.1 vs 8.6% @OncoAlert @myESMO @_SEOM
DrMirallas's tweet image. #ESMO25 Presidential Session 💥 🙌🏽 Practice Changing Trials 👉🏽 KEYNOTE-905: Enfortumab Vedotin+Pembro Cisplatin inelegible va Pembro #MIBC 🗣️ Dr. Vulsteke ✅ EFS NR vs 15.7m HR 0.40 ✅ OS NR vs 41.7m HR 0.50 ✅ pCR 57.1 vs 8.6% @OncoAlert @myESMO @_SEOM
DrMirallas's tweet image. #ESMO25 Presidential Session 💥 🙌🏽 Practice Changing Trials 👉🏽 KEYNOTE-905: Enfortumab Vedotin+Pembro Cisplatin inelegible va Pembro #MIBC 🗣️ Dr. Vulsteke ✅ EFS NR vs 15.7m HR 0.40 ✅ OS NR vs 41.7m HR 0.50 ✅ pCR 57.1 vs 8.6% @OncoAlert @myESMO @_SEOM
DrMirallas's tweet image. #ESMO25 Presidential Session 💥 🙌🏽 Practice Changing Trials 👉🏽 KEYNOTE-905: Enfortumab Vedotin+Pembro Cisplatin inelegible va Pembro #MIBC 🗣️ Dr. Vulsteke ✅ EFS NR vs 15.7m HR 0.40 ✅ OS NR vs 41.7m HR 0.50 ✅ pCR 57.1 vs 8.6% @OncoAlert @myESMO @_SEOM
1
9
18
3
2K
SScagliarini_'s profile picture. Medical Oncologist at AORN Cardarelli in Naples #GU cancers #RCC #kidneycancer #prostatecancer #bladdercancer #UC #Immunotherapy
Sarah Scagliarini, MD
 @SScagliarini_
Oct 18

#ESMO25 #MIBC #BladderCancer ➡️ Perioperative Pembro + EV. 😶 No words. 👏🏼 Just applause. 📣 Sound On. @myESMO

0
4
23
3
931
dralvaropinto's profile picture. Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid. Associate Professor of Medicine, Universidad Autónoma, Madrid.
Álvaro Pinto
 @dralvaropinto
Jun 1

Stop by our poster about intratumoral microbiota and its role in response to neoadjuvant chemo for muscle-invasive bladder carcinoma. It will be great if we can share some insights and comments about our work! #ASCO25 #MIBC #bladdercancer

dralvaropinto's tweet image. Stop by our poster about intratumoral microbiota and its role in response to neoadjuvant chemo for muscle-invasive bladder carcinoma. It will be great if we can share some insights and comments about our work! #ASCO25 #MIBC #bladdercancer
1
7
18
1
859
SWOG's profile picture. SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956.
SWOG Cancer Research Network
 @SWOG
14 h

S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0 or cT1) allow for bladder preservation? Systematic biopsies needed at post-NAT TURBT pre-registration. Co-PI: @siadaneshmand @uscnorris swog.org/clinical-trial…

SWOG's tweet image. S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0 or cT1) allow for bladder preservation? Systematic biopsies needed at post-NAT TURBT pre-registration. Co-PI: @siadaneshmand @uscnorris swog.org/clinical-trial…
0
3
4
0
330
ozdogan_md's profile picture. Oncologist. Cancer treatment & care in Turkey. Current advances, future directions and second opinion... Let's create a society which is not afraid of cancer!
Mustafa Özdoğan, MD
@ozdogan_md
Nov 21

FDA has approved perioperative pembrolizumab + enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) based on KEYNOTE-905 / EV-303. #BladderCancer #MIBC #Oncology #FDA #Pembrolizumab #EnfortumabVedotin #Immunotherapy #ADC #KEYNOTE905 #EV303…

ozdogan_md's tweet image. FDA has approved perioperative pembrolizumab + enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) based on KEYNOTE-905 / EV-303. #BladderCancer #MIBC #Oncology #FDA #Pembrolizumab #EnfortumabVedotin #Immunotherapy #ADC #KEYNOTE905 #EV303…
1
10
21
1
997
SScagliarini_'s profile picture. Medical Oncologist at AORN Cardarelli in Naples #GU cancers #RCC #kidneycancer #prostatecancer #bladdercancer #UC #Immunotherapy
Sarah Scagliarini, MD
 @SScagliarini_
Nov 21

#GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼

SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
0
2
10
0
627
ONAcom's profile picture. Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
OncologyNurseAdvisor
 @ONAcom
Nov 14

In patients with high-risk #MIBC, the 2-year locoregional failure-free survival rate was 87.1% with radiotherapy and 76.0% with observation. From @CancerTherAdvsr. bit.ly/499ZqtR #blcsm #bladdercancer

ONAcom's tweet card. In patients with locally advanced muscle-invasive bladder cancer who have undergone radical cystectomy and chemotherapy, adjuvant radiotherapy improves survival outcomes compared to observation only.
Adjuvant Radiotherapy Improves Locoregional Recurrence in High-Risk MIBC - Oncology Nurse Advisor
Source: oncologynurseadvisor.com
0
0
1
0
83
sciqst's profile picture. Precise references in medicine. https://t.co/gB5L99FK55 ByronInsight AG, Zurich, Switzerland
Raffaele Di Giacomo, PhD
@sciqst
Nov 14

It's encouraging to see advancements in patient-driven approaches for #MIBC. The combination treatment of sacituzumab govitecan and pembrolizumab could offer significant benefits. I'd be interested to know how this bladder-sparing approach impacts patient quality of life and…

0
0
0
0
18
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Nov 13

#SURE02 Trial: A patient-driven, bladder-sparing approach for #MIBC. @AndreaNecchi @MyUniSR joins @ERPlimackMD @FoxChaseCancer to discuss the combination of sacituzumab govitecan + pembrolizumab in a bladder-sparing approach for muscle-invasive #BladderCancer. #WatchNow >…

urotoday's tweet image. #SURE02 Trial: A patient-driven, bladder-sparing approach for #MIBC. @AndreaNecchi @MyUniSR joins @ERPlimackMD @FoxChaseCancer to discuss the combination of sacituzumab govitecan + pembrolizumab in a bladder-sparing approach for muscle-invasive #BladderCancer. #WatchNow >…
1
0
3
1
535
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Nov 10

#MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS

urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
0
7
16
4
1K
DrIacovelli's profile picture. Associate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy. Focused on GU cancers. Husband & father of 2 kids.
Roberto Iacovelli
@DrIacovelli
Nov 8

@giannatempopatr made a great lecture on #MIBC at 🇮🇹 #AIOM25 integrating experience, with trials knowledge and vision on this area. @AIOMtweet @urotoday @urotoday @OncoAlert @oncodaily

DrIacovelli's tweet image. @giannatempopatr made a great lecture on #MIBC at 🇮🇹 #AIOM25 integrating experience, with trials knowledge and vision on this area. @AIOMtweet @urotoday @urotoday @OncoAlert @oncodaily
DrIacovelli's tweet image. @giannatempopatr made a great lecture on #MIBC at 🇮🇹 #AIOM25 integrating experience, with trials knowledge and vision on this area. @AIOMtweet @urotoday @urotoday @OncoAlert @oncodaily
DrIacovelli's tweet image. @giannatempopatr made a great lecture on #MIBC at 🇮🇹 #AIOM25 integrating experience, with trials knowledge and vision on this area. @AIOMtweet @urotoday @urotoday @OncoAlert @oncodaily
1
2
13
0
542
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Nov 3

Cystectomy vs. Bladder Preservation: Weighing Options for Muscle-Invasive Bladder Cancer #MIBC. @BogdanaSchmidt @huntsmancancer & @mouwlab @DanaFarber join @UroDocAsh @MDAndersonNews in a debate on treatment options for muscle-invasive bladder cancer. #WatchNow on UroToday >…

urotoday's tweet image. Cystectomy vs. Bladder Preservation: Weighing Options for Muscle-Invasive Bladder Cancer #MIBC. @BogdanaSchmidt @huntsmancancer & @mouwlab @DanaFarber join @UroDocAsh @MDAndersonNews in a debate on treatment options for muscle-invasive bladder cancer. #WatchNow on UroToday >…
1
1
8
3
836
OncNewsCentral's profile picture. Oncology News Central (ONC) is the single destination for oncologists to stay abreast of the rapidly changing oncology landscape.
Oncology News Central
 @OncNewsCentral
Oct 31

🧬 Is muscle-invasive #BladderCancer care on the brink of a biomarker-driven shift? Historically, few prognostic or predictive #biomarkers have guided treatment decisions in #MIBC. But recent trial data and expert insights suggest that may be changing: bit.ly/4q1X6Ly

OncNewsCentral's tweet image. 🧬 Is muscle-invasive #BladderCancer care on the brink of a biomarker-driven shift? Historically, few prognostic or predictive #biomarkers have guided treatment decisions in #MIBC. But recent trial data and expert insights suggest that may be changing: bit.ly/4q1X6Ly
0
0
0
0
58
Uroweb's profile picture. We are: 18,000+ urologists. We do: Numerous scientific meetings, CME accreditation, scientific publications, research, awareness and more.
European Association of Urology (EAU)
 @Uroweb
Oct 30

Enfortumab vedotin in combination with pembrolizumab in the first-line setting demonstrated significant survival benefit as compared to chemotherapy in patients with metastatic bladder cancer. #MIBC #BladderCancer #EAUguidelines uroweb.org/guidelines/mus…

Uroweb's tweet card. The EAU Guidelines Panel for Muscle-invasive and Metastatic Bladder Cancer (MIBC) have prepared these guidelines to help urologists assess the evidence-based management of MIBC and to incorporate...
EAU Guidelines on MIBC - DISEASE MANAGEMENT - Uroweb
Source: uroweb.org
0
1
6
0
1K
ArabUrology's profile picture. Our mission is to promote excellence in urological care through education, research, and collaboration among healthcare professionals.
Arab Association of Urology
 @ArabUrology
Oct 30

A glimpse on Managing Muscle-Invasive Bladder Cancer: Current Treatment Strategies by Dr Abdulraheem Alshangiti #bladdercancerawareness #mibc #guoncology #cancertreatment #astrazeneca #aau #asu #eos @AstraZeneca

0
1
1
0
137
TargetedOnc's profile picture. Oncology news and insights from leading researchers and cancer centers.
Targeted Oncology
 @TargetedOnc
Oct 27

📹 WATCH: Perioperative enfortumab vedotin plus pembrolizumab in the EV-303 trial delivered highly significant, positive topline results, achieving 60% reduction in the risk of tumor recurrence in patients with muscle-invasive #BladderCancer. #MIBC hubs.li/Q03QcQPj0

0
2
2
0
316
oncolo_ms's profile picture. がん情報サイト「オンコロ」は、臨床試験を含む最新のがん情報や体験談、患者さんの調査に関する情報を発信しているWebサイトです。原則第2、第4金曜日、第3水曜日にがん情報オンラインセミナーを開催しています。 📺オンコロちゃんねる📺https://t.co/eCAVnYDI8C
オンコロ
 @oncolo_ms
Oct 27

第63回 #癌治療学会学術集会 が開催されました。「JSCO 2025 “Frontier”3」のセッションにて、「#筋層浸潤性膀胱がん（#MIBC）に対する周術期デュルバルマブとNAC併用の第3相試験：NIAGARA日本人部分集団解析」と題して西山博之先生（#筑波大学附属病院）が発表しました。 oncolo.jp/news/251027_js…

oncolo_ms's tweet card. 10月16～18日にパシフィコ横浜にて、第63回癌治療学会学術集会が開催された。「JSCO 2025 “Frontier”3」のセッションにて、「MIBCに対する周術期デュルバルマブとNAC併用の第3…
筋層浸潤性膀胱がんに対する術前・術後イミフィンジ、日本人サブ解析でも有効性を示す
Source: oncolo.jp
1
1
8
0
1K
stellanewslife's profile picture. 最新ニュースをお届けする https://t.co/TrisgKCaVP（https://t.co/TrisgKCaVP）。AIを活用し、主に科学技術の情報を効率的に発信中。誤りがあればご指摘ください。皆さまと共に正確な情報を共有します。お気軽にフォローしてください。
STELLANEWS.LIFE
@stellanewslife
Oct 26

テセントリク、ctDNAガイド下で筋層浸潤性膀胱がんの生存期間を大幅に延長、第3相 Tecentriq improves survival in ctDNA-guided adjuvant treatment for MIBC – Phase 3 IMvigor011 stellanews.life/technology_cat… #Tecentriq #Atezolizumab #MIBC #ctDNA #AdjuvantTherapy #MRD #Signatera #IMvigor011…

stellanewslife's tweet card. ロシュはテセントリクが筋層浸潤性膀胱がんの再発リスクをctDNA検査で特定し、死亡・再発リスクを大幅に低減したと発表。
テセントリク、ctDNAガイド下で筋層浸潤性膀胱がんの生存期間を大幅に延長、第3相 | STELLANEWS.LIFE
Source: stellanews.life
0
0
1
0
138
stellanewslife's profile picture. 最新ニュースをお届けする https://t.co/TrisgKCaVP（https://t.co/TrisgKCaVP）。AIを活用し、主に科学技術の情報を効率的に発信中。誤りがあればご指摘ください。皆さまと共に正確な情報を共有します。お気軽にフォローしてください。
STELLANEWS.LIFE
@stellanewslife
Oct 26

膀胱がん生存改善、キイトルーダ＋PadcevがFDA優先審査、初の周術期免疫療法へ KEYTRUDA + Padcev granted FDA Priority Review in bladder cancer, aiming for first perioperative immunotherapy stellanews.life/technology_cat… #BladderCancer #MIBC #KEYTRUDA #Padcev #PerioperativeTherapy…

stellanewslife's tweet card. 膀胱がん周術期治療としてキイトルーダ＋Padcev併用がFDA優先審査。生存期間と病理奏効を大幅に改善。承認なら新標準に。
膀胱がん生存改善、キイトルーダ＋PadcevがFDA優先審査、初の周術期免疫療法へ | STELLANEWS.LIFE
Source: stellanews.life
0
0
0
0
113
MibcM's profile picture. 気まぐれ垢。。猫すきな人、読書すきな人、音楽すきな人etc。。お気軽にどーぞ。。

みぃ

@MibcM
kyztSgDSCExMibc's profile picture. 25卒

だ🤢25

@kyztSgDSCExMibc
mibc_JoseMaria's profile picture. Pr. José Maria Savazzi, Pastor e Presidente do Conselho de Missões, Igreja Batista do Caminho Tenda , Igreja Missionária em Células no modelo dos 12

José Maria Savazzi

@mibc_JoseMaria
MIBC_NSU's profile picture. Marketing and International Business Club is one of the functional business clubs which is operating under the Department of Marketing & International Business

Marketing and International Business Club (NSU)

@MIBC_NSU
mibcco's profile picture. مهندسین مشاور ساختمانهای هوشمند خاورمیانه شرکت MIBC در سال 1384 با هدف ارایه خدمات کنترل هوشمنـد ساختمـان در تـهـران تاسیـس گـردید .

MIBC

@mibcco
mibcMoscowCity's profile picture. #moscowcity #moscowcitytowers #moscowcitylife #москвасити #ммдц #сити #moscowcityrealty #небоскребы #недвижимость #апартаменты #офисы #снять #купить

Недвижимость ММДЦ Москва-Сити

@mibcMoscowCity
MIbcHOmckcbxnyp's profile picture.

いとーゆー

@MIbcHOmckcbxnyp
6k2OxMIBcT63hFi's profile picture. 岡山・津山→香川大法学部 野球⚾️→ラクロス🥍 3回生

小林海輝

@6k2OxMIBcT63hFi
gyepebizEq6MIBc's profile picture.

あるまじろ

@gyepebizEq6MIBc
MibcPort's profile picture. University and College

MIBC PORT HARCOURT

@MibcPort
IsabelMibc's profile picture. licenciada en medicina y derecho. Republicana y roja

Maria Isabel Bermude

@IsabelMibc
Mibc_'s profile picture.

isa

@Mibc_
ocbF8Pfc7mibcYm's profile picture. ‏متفائله بالخير

........

@ocbF8Pfc7mibcYm
MiBC's profile picture.

Marija

@MiBC
AmberMibc's profile picture. Believer 🙌🏼. Woman. Mom. Daughter. Sister. Friend. Treating the demon that is inflammatory breast cancer since 9/2018. Metastatic since 5/2020.

amberVScancer

@AmberMibc
mibc_16's profile picture. Bla bla bla blabla bla....biografía biografía biografía

moises barrientos

@mibc_16
mibcPH's profile picture. Macpherson International Business Consultancy offers our clientele the following services: International Student Placement, Accreditation and Collaboration.

MIBC Philippines

@mibcPH
mibcafrica's profile picture. Institution qui forme à la sagesse économique, à l’intégralité humaine et à la durabilité pour résoudre le problème de l’inadéquation compétence-emploi

MIBC - Maya International Business Consulting

@mibcafrica
_MIBC's profile picture. MENGATASI KERUSUHAN YANG ADA DENGAN NAMBAHIN RUSUH Akun bercanda ya!! #MIBC | #DIEMLO

M . I . B . C

@_MIBC
MibcRizal's profile picture.

sukhairizal

@MibcRizal
Uuz2zW5mibcScPp's profile picture. 数日前にギターを始めた超初心者です！ twitterも初めてなので色々教えてくれたらすごい嬉しいです😆

ミハル

@Uuz2zW5mibcScPp
AeQ7mibcUHIRaFs's profile picture. ‘00 雪国

マタ・ハリソン

@AeQ7mibcUHIRaFs
mibc315's profile picture. 千葉県松戸市の美容サロンです。増毛エクステスクールの講師です。育毛、コルギ、ハーバルピール、よもぎ蒸しなど😃乳酸ピールもおすすめです💕

医療提携　松戸育毛美容センター

@mibc315
VqqMibcWIeB_r4o's profile picture.

大阪市立海老江東小学校

@VqqMibcWIeB_r4o
ID2sMIBcT4FYfwQ's profile picture.

اماني

@ID2sMIBcT4FYfwQ
LkMIBcE02E65937's profile picture. アマチュア好き(基本大学野球)/ 関東鷲/#1#19.#27.#34/ 現地成績 6勝7敗1分(2024) 9勝7敗1分(2025)

ペニーランドリー

@LkMIBcE02E65937
MIBC_PHC's profile picture. OFFICIAL ACCOUNT OF THE MOUNTAIN-TOP INT'L BIBLE COLLEGE PORT HARCOURT CAMPUS | FOLLOW US ON IG: @mibcphc |

MIBC PORT HARCOURT

@MIBC_PHC
51K40Lt172MIbcJ's profile picture. ハジ→が一番すき！Hilcrhyme　back number 八二　バスケ部キャプテン元#16現#5東総選抜#4 気軽によろしくー

加納ゆうき

@51K40Lt172MIbcJ
IgniteMIBC's profile picture. Evening Service at Middle Island Baptist Church a 698 Wading River Hollow Road, Middle Island NY

Ignite MIBC

@IgniteMIBC
MiBCAlliance's profile picture. We are a revolutionary not for profit organisation that cares about you and your community! Business @ The Speed of Trust

MiBC Alliance

@MiBCAlliance
3Xx3Z4MibcWHIyp's profile picture. 釣りは２回楽しめる

伸幸 林

@3Xx3Z4MibcWHIyp
GloriaMibc's profile picture. Artes Manualidades

Gloria Caceres

@GloriaMibc
MasakaMibc's profile picture. We are a christian Volunteer Ministry of Masaka independent Baptist church in Uganda.

MIBC Prison Ministry Masaka

@MasakaMibc
oYmZMEW4MIbcHou's profile picture.

أحمدالشافعى

@oYmZMEW4MIbcHou
Chelle5778Mibc's profile picture.

michelle patrlck

@Chelle5778Mibc
mibc2991's profile picture. ✈️➡️https://t.co/flbeaU3XGv 🤖➡️https://t.co/GSWKfG6xfk ❌➡️@naomi_gene80254

等夏天等秋天

@mibc2991
MongoliaIndiaBC's profile picture. Монгол Энэтхэгийн Бизнес Зөвлөл ENVISION ENGAGE EMPOWER

MIBC

@MongoliaIndiaBC
king_mibc's profile picture.

たっつ

@king_mibc
MibcBANaA812403's profile picture.

ひな

@MibcBANaA812403
mibc___'s profile picture.

_

@mibc___
MIBC2018's profile picture. January 24-28, 2018

Miami International Ballet Competition

@MIBC2018
melaniebarrios5's profile picture. Sonrie, yo existo =)

@MIBC-23

@melaniebarrios5
gMIbc3QDXiRZ7fG's profile picture. Michael lebbie

099900650

@gMIbc3QDXiRZ7fG
mibc24's profile picture.

M

@mibc24
mariaisabel1203's profile picture. Malaga

mibc

@mariaisabel1203
Chelle_MIBC's profile picture. Hi! I am a brand new Mary Kay Independent Beauty Consultant! http://t.co/JXrRYjnMfR

Chelle Samaniego

@Chelle_MIBC
mibc_bowling's profile picture. Official twitter account for Melaka International Bowling Centre

mibcbowling

@mibc_bowling
2Jrrkcac4CqMIbc's profile picture. ‏الرياضات كرة القدم المصارعة الحرة العالمية الترفيهية الفنون القتالية المختلطة الأخبار تعليق رياضي الترفيه نمط الحياة

فحل صنعا

@2Jrrkcac4CqMIbc
MIBoxCompany's profile picture.

MIBC

@MIBoxCompany
mibc23q's profile picture.

はやさかみいな

@mibc23q
DrFelixGuerrero's profile picture. MD PhD UroOncology @urologia12 @ROC_Urologia @HMHOSPITALES Scient Committee @GuardConsortium “Try not to become a man of success, rather become a man of value”
Félix Guerrero-Ramos
@DrFelixGuerrero
Oct 11

‼️Primary vs progressive #MIBC 🤼Controversial topic 📉We publish on this in the October issue of @actasurologicas @RodriguezFaba 🏥@Urologia12 @cgdelcanizo @MarioHArroyo @H12Octubre 🔗Read it here: t.ly/cdaAk

DrFelixGuerrero's tweet image. ‼️Primary vs progressive #MIBC 🤼Controversial topic 📉We publish on this in the October issue of @actasurologicas @RodriguezFaba 🏥@Urologia12 @cgdelcanizo @MarioHArroyo @H12Octubre 🔗Read it here: t.ly/cdaAk
DrFelixGuerrero's tweet image. ‼️Primary vs progressive #MIBC 🤼Controversial topic 📉We publish on this in the October issue of @actasurologicas @RodriguezFaba 🏥@Urologia12 @cgdelcanizo @MarioHArroyo @H12Octubre 🔗Read it here: t.ly/cdaAk
DrFelixGuerrero's tweet image. ‼️Primary vs progressive #MIBC 🤼Controversial topic 📉We publish on this in the October issue of @actasurologicas @RodriguezFaba 🏥@Urologia12 @cgdelcanizo @MarioHArroyo @H12Octubre 🔗Read it here: t.ly/cdaAk
0
15
33
6
2K
SWOG's profile picture. SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956.
SWOG Cancer Research Network
 @SWOG
14 h

S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0 or cT1) allow for bladder preservation? Systematic biopsies needed at post-NAT TURBT pre-registration. Co-PI: @siadaneshmand @uscnorris swog.org/clinical-trial…

SWOG's tweet image. S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0 or cT1) allow for bladder preservation? Systematic biopsies needed at post-NAT TURBT pre-registration. Co-PI: @siadaneshmand @uscnorris swog.org/clinical-trial…
0
3
4
0
330
ozdogan_md's profile picture. Oncologist. Cancer treatment & care in Turkey. Current advances, future directions and second opinion... Let's create a society which is not afraid of cancer!
Mustafa Özdoğan, MD
@ozdogan_md
Nov 21

FDA has approved perioperative pembrolizumab + enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) based on KEYNOTE-905 / EV-303. #BladderCancer #MIBC #Oncology #FDA #Pembrolizumab #EnfortumabVedotin #Immunotherapy #ADC #KEYNOTE905 #EV303…

ozdogan_md's tweet image. FDA has approved perioperative pembrolizumab + enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) based on KEYNOTE-905 / EV-303. #BladderCancer #MIBC #Oncology #FDA #Pembrolizumab #EnfortumabVedotin #Immunotherapy #ADC #KEYNOTE905 #EV303…
1
10
21
1
997
AndreaNecchi's profile picture. Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Andrea Necchi
@AndreaNecchi
Aug 27

📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4…

AndreaNecchi's tweet image. 📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4…
AndreaNecchi's tweet image. 📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4…
3
54
141
29
19K
SScagliarini_'s profile picture. Medical Oncologist at AORN Cardarelli in Naples #GU cancers #RCC #kidneycancer #prostatecancer #bladdercancer #UC #Immunotherapy
Sarah Scagliarini, MD
 @SScagliarini_
Nov 21

#GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼

SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
SScagliarini_'s tweet image. #GURetreat25 @AndreaNecchi ? What happened in Bladder Cancer? 📣 A lot of news! But BCG is still the King… And we are waiting for data in #MIBC Cis Elegible patients! Amazing session!! @UroDocAsh @BrigidaMaiorano 👏🏼
0
2
10
0
627
DrIacovelli's profile picture. Associate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy. Focused on GU cancers. Husband & father of 2 kids.
Roberto Iacovelli
@DrIacovelli
Oct 18

New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos

DrIacovelli's tweet image. New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos
DrIacovelli's tweet image. New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos
DrIacovelli's tweet image. New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos
DrIacovelli's tweet image. New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1 @OncoAlert @GUOncologyNow @Uromigos
2
25
57
12
4K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Nov 10

#MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS

urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
urotoday's tweet image. #MIBC – What you should be doing today and what we will be doing tomorrow. Presentation by @JoshMeeks @NUFeinbergMed. #LUGPA2025 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4ozyvMV @UrologyUS
0
7
16
4
1K
Uroweb's profile picture. We are: 18,000+ urologists. We do: Numerous scientific meetings, CME accreditation, scientific publications, research, awareness and more.
European Association of Urology (EAU)
 @Uroweb
Apr 6, 2023

Standard treatment for urothelial muscle invasive bladder cancer is radical cystectomy, but RC only provides 5-year survival in ~50% of patients. Review the #EAUGuidelines on #MIBC disease management in this @CheatUrology #EAUUrologyCheatSheets. d56bochluxqnz.cloudfront.net/media/Cheat-sh…

Uroweb's tweet image. Standard treatment for urothelial muscle invasive bladder cancer is radical cystectomy, but RC only provides 5-year survival in ~50% of patients. Review the #EAUGuidelines on #MIBC disease management in this @CheatUrology #EAUUrologyCheatSheets. d56bochluxqnz.cloudfront.net/media/Cheat-sh…
1
42
102
18
15K
DrFelixGuerrero's profile picture. MD PhD UroOncology @urologia12 @ROC_Urologia @HMHOSPITALES Scient Committee @GuardConsortium “Try not to become a man of success, rather become a man of value”
Félix Guerrero-Ramos
@DrFelixGuerrero
Jan 18, 2024

Dr. Solsona back on the stage with a great talk on #bladderpreservation for #MIBC at the IVO Masterclass Coordinators: @mjuanfi81 @DominguezEscrig @GuardConsortium

DrFelixGuerrero's tweet image. Dr. Solsona back on the stage with a great talk on #bladderpreservation for #MIBC at the IVO Masterclass Coordinators: @mjuanfi81 @DominguezEscrig @GuardConsortium
0
8
19
0
2K
Uroweb's profile picture. We are: 18,000+ urologists. We do: Numerous scientific meetings, CME accreditation, scientific publications, research, awareness and more.
European Association of Urology (EAU)
 @Uroweb
Jan 9

New Cheat Sheet on #MIBC! It covers adjuvant chemotherapy and immunotherapy roles, recent advancements in metastatic UC treatment, and combination therapy standards like EV + Pembrolizumab. #BladderCancer #EAUguidelines Download here: uroweb.org/guidelines/mus…

Uroweb's tweet image. New Cheat Sheet on #MIBC! It covers adjuvant chemotherapy and immunotherapy roles, recent advancements in metastatic UC treatment, and combination therapy standards like EV + Pembrolizumab. #BladderCancer #EAUguidelines Download here: uroweb.org/guidelines/mus…
1
47
133
77
21K
drenriquegrande's profile picture. Medical Oncology Department Director at Quironsalud Madrid. Opinions are my own. https://t.co/DrJu4J331O
Enrique Grande
@drenriquegrande
Sep 8

⚡️ Is perioperative #durvalumab cost-effective in #MIBC? 📊 New study using German healthcare data: – +0.21 QALYs – +€13,162 cost – ICER: €61,006/QALY ✅ Cost-effective at €100K WTP (76.5% probability) #BladderCancer ejcancer.com/article/S0959-…

drenriquegrande's tweet image. ⚡️ Is perioperative #durvalumab cost-effective in #MIBC? 📊 New study using German healthcare data: – +0.21 QALYs – +€13,162 cost – ICER: €61,006/QALY ✅ Cost-effective at €100K WTP (76.5% probability) #BladderCancer ejcancer.com/article/S0959-…
drenriquegrande's tweet image. ⚡️ Is perioperative #durvalumab cost-effective in #MIBC? 📊 New study using German healthcare data: – +0.21 QALYs – +€13,162 cost – ICER: €61,006/QALY ✅ Cost-effective at €100K WTP (76.5% probability) #BladderCancer ejcancer.com/article/S0959-…
0
5
22
7
2K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Oct 20

#IMvigor011: A phase 3 trial of ctDNA-guided adjuvant atezolizumab vs pbo in #MIBC. Presentation by @tompowles1 @QMBCI. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/477HEoc @myESMO

urotoday's tweet image. #IMvigor011: A phase 3 trial of ctDNA-guided adjuvant atezolizumab vs pbo in #MIBC. Presentation by @tompowles1 @QMBCI. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/477HEoc @myESMO
urotoday's tweet image. #IMvigor011: A phase 3 trial of ctDNA-guided adjuvant atezolizumab vs pbo in #MIBC. Presentation by @tompowles1 @QMBCI. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/477HEoc @myESMO
urotoday's tweet image. #IMvigor011: A phase 3 trial of ctDNA-guided adjuvant atezolizumab vs pbo in #MIBC. Presentation by @tompowles1 @QMBCI. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/477HEoc @myESMO
urotoday's tweet image. #IMvigor011: A phase 3 trial of ctDNA-guided adjuvant atezolizumab vs pbo in #MIBC. Presentation by @tompowles1 @QMBCI. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/477HEoc @myESMO
1
5
9
2
836
siadaneshmand's profile picture. Professor of Urology and Oncology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic Oncology Fellowship Director USC
Sia Daneshmand, M.D.
@siadaneshmand
Sep 21, 2024

⁦⁦@saumyg⁩ presenting trial concept - do all pts with #MIBC need neoadjuvant chemotherapy? LUMBER-NAC #ibcn ⁦@Decipher_VCYT⁩ ⁦@BladderCancerUS⁩

siadaneshmand's tweet image. ⁦⁦@saumyg⁩ presenting trial concept - do all pts with #MIBC need neoadjuvant chemotherapy? LUMBER-NAC #ibcn ⁦@Decipher_VCYT⁩ ⁦@BladderCancerUS⁩
3
5
39
0
2K
brookmans76's profile picture. Professor of Urology @LMU_Muenchen, SVP Therapeutic Area Head Urologic Oncology @AuraBiosciences - former VP R&D J&J - Sports Medicine 🚵‍♀️Passionate Cyclist
Sabine D. Brookman-May
 @brookmans76
Oct 21

Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday

brookmans76's tweet image. Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday
brookmans76's tweet image. Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday
brookmans76's tweet image. Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday
brookmans76's tweet image. Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday
2
6
25
3
2K
AndreaNecchi's profile picture. Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Andrea Necchi
@AndreaNecchi
Feb 17, 2023

The one and only @shilpaonc leading the stage at #GU23 with outstanding lecture on periop therapies in #MIBC @urotoday @ASCO @GTumors

AndreaNecchi's tweet image. The one and only @shilpaonc leading the stage at #GU23 with outstanding lecture on periop therapies in #MIBC @urotoday @ASCO @GTumors
AndreaNecchi's tweet image. The one and only @shilpaonc leading the stage at #GU23 with outstanding lecture on periop therapies in #MIBC @urotoday @ASCO @GTumors
2
7
32
2
3K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Oct 21

#PUNCH02: Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response #MIBC patients. Presentation by Bin Huang, MD. #ESMO25 written coverage by @RKSayyid >…

urotoday's tweet image. #PUNCH02: Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response #MIBC patients. Presentation by Bin Huang, MD. #ESMO25 written coverage by @RKSayyid >…
urotoday's tweet image. #PUNCH02: Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response #MIBC patients. Presentation by Bin Huang, MD. #ESMO25 written coverage by @RKSayyid >…
urotoday's tweet image. #PUNCH02: Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response #MIBC patients. Presentation by Bin Huang, MD. #ESMO25 written coverage by @RKSayyid >…
urotoday's tweet image. #PUNCH02: Interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response #MIBC patients. Presentation by Bin Huang, MD. #ESMO25 written coverage by @RKSayyid >…
1
6
12
4
1K
CancerNetwrk's profile picture. Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.
CancerNetwork®
@CancerNetwrk
Oct 23

Enfortumab vedotin plus pembrolizumab as neoadjuvant therapy then adjuvant therapy reduced the risk of recurrence, progression, or death by 60% vs surgery alone in an MIBC population. hubs.li/Q03PNbq00 #blcsm #MIBC

CancerNetwrk's tweet image. Enfortumab vedotin plus pembrolizumab as neoadjuvant therapy then adjuvant therapy reduced the risk of recurrence, progression, or death by 60% vs surgery alone in an MIBC population. hubs.li/Q03PNbq00 #blcsm #MIBC
0
1
4
0
302
DrFelixGuerrero's profile picture. MD PhD UroOncology @urologia12 @ROC_Urologia @HMHOSPITALES Scient Committee @GuardConsortium “Try not to become a man of success, rather become a man of value”
Félix Guerrero-Ramos
@DrFelixGuerrero
Apr 25, 2023

📝 Happy to share our paper at @JUrology reporting results of TAR-200-103 phase I trial w/ TAR-200 in #MIBC unfit for cystectomy 👥 Collaboration w/ @RodriguezFaba @joanfundi among others 🤓 Take a look: shorturl.at/sHUW5 😃 Exciting times ahead for #bladdercancer patients

DrFelixGuerrero's tweet image. 📝 Happy to share our paper at @JUrology reporting results of TAR-200-103 phase I trial w/ TAR-200 in #MIBC unfit for cystectomy 👥 Collaboration w/ @RodriguezFaba @joanfundi among others 🤓 Take a look: shorturl.at/sHUW5 😃 Exciting times ahead for #bladdercancer patients
DrFelixGuerrero's tweet image. 📝 Happy to share our paper at @JUrology reporting results of TAR-200-103 phase I trial w/ TAR-200 in #MIBC unfit for cystectomy 👥 Collaboration w/ @RodriguezFaba @joanfundi among others 🤓 Take a look: shorturl.at/sHUW5 😃 Exciting times ahead for #bladdercancer patients
DrFelixGuerrero's tweet image. 📝 Happy to share our paper at @JUrology reporting results of TAR-200-103 phase I trial w/ TAR-200 in #MIBC unfit for cystectomy 👥 Collaboration w/ @RodriguezFaba @joanfundi among others 🤓 Take a look: shorturl.at/sHUW5 😃 Exciting times ahead for #bladdercancer patients
0
11
24
0
2K
AndreaNecchi's profile picture. Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Andrea Necchi
@AndreaNecchi
Jul 29, 2024

Happy to provide the first announcement of a global consensus meeting that will be held in person and virtually on Saturday December 14 2024 at @SanRaffaeleMI the day after our #GURetreat24 | the topic will be the definition of clinical CR after neoadjuvant therapies for #MIBC

AndreaNecchi's tweet image. Happy to provide the first announcement of a global consensus meeting that will be held in person and virtually on Saturday December 14 2024 at @SanRaffaeleMI the day after our #GURetreat24 | the topic will be the definition of clinical CR after neoadjuvant therapies for #MIBC
2
12
37
2
2K
nataliagandur's profile picture. Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte Views Mine
Dra. María Natalia Gandur Quiroga
@nataliagandur
Aug 10, 2023

💫🌟Revolutionizing #MIBC Treatment: VI-RADS Scores Predict Success of #Immunotherapy 🚀🩺🌟💫 #MIBCResearch #InnovativeMedicine🌟💫 📢 **Exciting Findings**: PURE-01 trial reveals groundbreaking insights! 🌟 VI-RADS Power: Predicting post-neoadjuvant immunotherapy response in…

nataliagandur's tweet image. 💫🌟Revolutionizing #MIBC Treatment: VI-RADS Scores Predict Success of #Immunotherapy 🚀🩺🌟💫 #MIBCResearch #InnovativeMedicine🌟💫 📢 **Exciting Findings**: PURE-01 trial reveals groundbreaking insights! 🌟 VI-RADS Power: Predicting post-neoadjuvant immunotherapy response in…
0
12
20
3
3K

Something went wrong.


Something went wrong.


United States Trends